Tralokinumab clinical trials
Also written CAT-354.
How each study uses tralokinumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tralokinumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 27 Dec 2021 · ADBRY · BLA 761180 (FDA, Drugs@FDA)
- European Union
- 17 Jun 2021 · Adtralza · EMEA/H/C/005255 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
32 studies that test it; most in 2018 (6)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 3 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 6 |
| 2020 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 28 · Other 4
LEO Pharma (13) · MedImmune LLC (9) · AstraZeneca (6) · Prof. Dr. Stephan Weidinger (1) · Emma Guttman (1) · University of California, San Francisco (1) · Psoriasis Treatment Center of Central New Jersey (1)
Often tested with
Tested in the same studies.
Triamcinolone (1) · Fluorouracil (1) · Calcipotriene (1) · Tapinarof (1) · Crisaborole (1) · Tacrolimus (1) · Adalimumab (1) · Etanercept (1)
Studies
Open first, then newest update. How each study uses tralokinumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 32
- A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic DermatitisRecruitingPhase 3LEO PharmaNCT06311682Written as Tralokinumab + TCSHow we know
- Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingPhase 4University of California, San FranciscoNCT07352566Written as TralokinumabHow we know
- A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic TherapyCompletedPhase 3LEO PharmaNCT05958407Written as TralokinumabHow we know
- Tralokinumab for Dupilumab FailuresTerminatedPhase 4Psoriasis Treatment Center of Central New JerseyNCT06773455Written as tralokinumabHow we know
- Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)CompletedPhase 2LEO PharmaNCT05388760Written as TralokinumabHow we know
- Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)CompletedPhase 3LEO PharmaNCT05194540Written as TralokinumabHow we know
- Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)CompletedPhase 3LEO PharmaNCT03131648Written as TralokinumabHow we know
- Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7CompletedPhase 3LEO PharmaNCT03761537Written as TralokinumabHow we know
- Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)CompletedPhase 3LEO PharmaNCT03160885Written as TralokinumabHow we know
- Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).CompletedPhase 3LEO PharmaNCT03526861Written as TralokinumabHow we know
- Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTENDCompletedPhase 3LEO PharmaNCT03587805Written as TralokinumabHow we know
- Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)CompletedPhase 2LEO PharmaNCT03562377Written as TralokinumabHow we know
- Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic DermatitisCompletedPhase 3LEO PharmaNCT04587453Written as TralokinumabHow we know
- Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3CompletedPhase 3LEO PharmaNCT03363854Written as TralokinumabHow we know
- Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4CompletedPhase 1LEO PharmaNCT03556592Written as TralokinumabHow we know
- Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier FunctionCompletedPhase 2Prof. Dr. Stephan WeidingerNCT04556461Written as TralokinumabHow we know
- A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia AreataCompletedPhase 2Emma GuttmanNCT02684097Written as TralokinumabHow we know
- A Study to Evaluate the Safety of Tralokinumab in Adults and Adolescents With Uncontrolled AsthmaTerminatedPhase 3AstraZenecaNCT02902809Written as Tralokinumab open-labelHow we know
- Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent AsthmaCompletedPhase 3AstraZenecaNCT02281357Written as TralokinumabHow we know
- Study to Evaluate Efficacy & Safety of Tralokinumab in Subjects With Asthma Inadequately Controlled on CorticosteroidsCompletedPhase 2AstraZenecaNCT02449473Written as TralokinumabHow we know
Codes
What other systems call tralokinumab · ClinicalTrials.gg INT006111
- MeSH (NLM) C574065tralokinumabOne source NLM
- UNII (FDA) GK1LYB375ATRALOKINUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2589225One source FDA
- Wikidata Q7833105TralokinumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152710TralokinumabOne source FDA
- DrugBank DB12169One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C574065 | tralokinumab | One source NLM |
| UNII (FDA) | GK1LYB375A | TRALOKINUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2589225 | — | One source FDA |
| Wikidata | Q7833105 | Tralokinumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152710 | Tralokinumab | One source FDA |
| DrugBank | DB12169 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.